GSK wins US approval for Nelkarmi in previously treated ALK-positive lung cancer

Key highlights
  • Approval is based on phase I/II ALKOVE-1, which included 222 patients with previously treated ALK-positive NSCLC.
  • Confirmed response rates were 49% after alectinib alone and 32% after at least two ALK inhibitors plus chemotherapy.
  • Intracranial response rates were 55% and 26%, respectively, among patients with measurable CNS metastases.
  • Common adverse reactions included hepatotoxicity, musculoskeletal pain, constipation, dysgeusia, peripheral neuropathy, edema and fatigue.

FDA approval

The FDA granted accelerated approval to GSK’s Nelkarmi (neladalkib) for adults with locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC) previously treated in the unresectable or metastatic setting. Eligible patients must have received either alectinib as their only prior ALK inhibitor, or at least two ALK inhibitors and platinum-based chemotherapy.

Clinical results

Approval was based on the phase I/II ALKOVE-1 trial. Among patients previously treated with alectinib alone, the confirmed overall response rate was 49% (33/67); among those treated with at least two ALK inhibitors and chemotherapy, it was 32% (50/155). Responses lasted at least 12 months in 52% and 51% of responders, respectively.

For patients with measurable central nervous system metastases, intracranial response rates were 55% after alectinib alone and 26% after at least two ALK inhibitors and chemotherapy.

Safety and further evaluation

The most common adverse reactions, occurring in at least 20% of patients, were hepatotoxicity, musculoskeletal pain, constipation, dysgeusia, peripheral neuropathy, edema and fatigue. Adverse reactions led to permanent discontinuation in 5% of patients, most often because of hepatotoxicity.

Nelkarmi is also being evaluated in the ongoing phase III ALKAZAR trial in patients who have not received an ALK inhibitor, and in other solid tumours.

Source: GSK

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time. See our Privacy Policy.

Related articles

13 September 2026
GSK: registrational data support first-line expansion of Jideytro in ROS1‑positive NSCLC

Phase I/II ARROS‑1 data show 94% ORR, 90% progression‑free at 12 months and strong intracranial activity; supplemental US submission planned for 2026.

22 July 2026
GSK's Jideytro (zidesamtinib) approved in US for ROS1‑positive NSCLC

FDA clears zidesamtinib for adults with advanced ROS1‑positive NSCLC after prior ROS1 inhibitor; ARROS‑1 showed 44% ORR and durable responses, including in brain metastases.

15 July 2026
GSK completes Nuvalent acquisition, adds three NSCLC assets

Adds three NSCLC assets including two under FDA review for ROS1 and ALK with target decisions later this year; expected 2026 launches; deal valued at ~$10.6bn.

24 June 2026
GSK commences tender offer for Nuvalent

Tender offer launched at $124 per share; requires majority of Class A shares tendered and HSR clearance; no guaranteed delivery; offer set to expire July 14, 2026.

9 June 2026
GSK to acquire Nuvalent for $10.6 billion

Includes two late-stage ROS1 and ALK NSCLC inhibitors under FDA review for 2026 decisions, plus a HER2 candidate; expected to be accretive to profit from 2027 and funded by debt and cash.